BMO Capital raised Azek's price target to $57 and maintains a Market Perform rating, citing benefits for shareholders. Truist suggests buying James Hardie post-Azek deal. Stephens downgraded Azek to Equal Weight.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing